Terbogrel

Terbogrel (INN) blocks thromboxanes and is expected to be useful in treating the vasoconstricting and platelet-aggregating action of this compound. Terbogrel is an orally available thromboxane A₂ receptor antagonist and a thromboxane A synthase inhibitor. The drug was developed by Boehringer Ingelheim.

A phase 2 clinical trial of Terbogrel was discontinued due to its induction of leg pain.